|Bid||98.70 x 1100|
|Ask||98.75 x 1100|
|Day's Range||96.59 - 98.93|
|52 Week Range||79.96 - 131.54|
|Beta (3Y Monthly)||0.65|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 2, 2019 - May 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||117.14|
LivaNova PLC NASDAQ/NGS:LIVNView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for LIVN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding LIVN are favorable, with net inflows of $3.07 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
LivaNova PLC (LIVN), a market-leading medical technology company, today announced Trui Hebbelinck has been appointed Chief Human Resources Officer for the Company. Hebbelinck will lead global human resources, serve on the Executive Leadership Team and report to Chief Executive Officer Damien McDonald. “Trui brings incredible expertise to LivaNova and has a history of exceptional results,” said McDonald.
LivaNova PLC (LIVN), a market-leading medical technology company, today announced it will present three abstracts supporting the use of implantable neuromodulation technology to treat chronic heart failure during the American College of Cardiology 68th Annual Scientific Session (ACC 2019) from March 16-18 in New Orleans, USA. The LivaNova VITARIA® System delivers Autonomic Regulation Therapy (ART) using Vagus Nerve Stimulation (VNS) to treat patients with chronic, symptomatic heart failure with reduced ejection fraction (HFrEF). VITARIA is currently being used to study the effects of ART in a prospective, international, randomized, controlled clinical trial (ANTHEM-HFrEF Pivotal Study).
NEW YORK, March 06, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
LivaNova PLC , a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2018.
LivaNova PLC (LIVN), a market-leading medical technology company, announced today that given the increasing viability of Valve-in-Valve (ViV) procedures, it has added new safety and technical information to the Perceval U.S. Instructions For Use (IFUs). This addition was made following completion of the Company’s application to the U.S. Food and Drug Administration. The use of transcatheter valves in failed bioprostheses has recently been recognized in both American and European Guidelines as an option for patients at high surgical risk.
LivaNova PLC (LIVN), a market-leading medical technology company, today announced that Japan’s Ministry of Health, Labour and Welfare granted national reimbursement for the Company’s Perceval® sutureless aortic heart valve to treat aortic valve disease. “With national reimbursement for Perceval, an innovative and trusted valve platform, we can provide patients and clinicians in Japan with an innovative and effective option for aortic heart valve replacement,” said Noriaki Kawana, President of LivaNova Japan. As the only 100-percent sutureless valve for aortic valve replacement, Perceval is designed to be highly versatile and suitable for a wide range of surgical approaches, including traditional and minimally invasive.
LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LivaNova PLC (LIVN), a market-leading medical technology company, today recognized that the U.S. Centers for Medicare & Medicaid Services (CMS) finalized its National Coverage Determination (NCD) for the LivaNova Vagus Nerve Stimulation Therapy® (VNS Therapy) System for Treatment-Resistant Depression (TRD). Per its final decision, CMS has modified the NCD for VNS Therapy for TRD to include feedback received during the comment period in a manner that aligns the Coverage with Evidence Development (CED) framework with current indications and standard of practice for clinical study design in this disease state.
LivaNova PLC (LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth quarter and full-year 2018 results on Wednesday, Feb. 27, 2019 at 1 p.m. London time (8 a.m. Eastern Standard Time). The Company will release its fourth quarter and full-year 2018 results prior to the call.
LivaNova PLC (LIVN), a market-leading medical technology company, today announced the publication of three separate studies highlighting the unique performance of its sutureless aortic valve, Perceval®. The results from the Perceval Aortic Heart Valve Study in North America, performed under a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE), were published in the Journal of Thoracic and Cardiovascular Surgery1.
NEW YORK, Jan. 03, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
The fourth quarter was a rough one for most investors, as fears of a rising interest rate environment in the U.S, a trade war with China, and a more or less stagnant Europe, weighed heavily on the minds of investors. Both the S&P 500 and Russell 2000 sank as a result, with the Russell 2000, […]
NEW YORK, Nov. 29, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
LivaNova PLC (LIVN), a market-leading medical technology company, today announced it has joined forces with actor and epilepsy advocate Greg Grunberg. The partnership kicked off at the Epilepsy Awareness Day at Disneyland Education Expo, where Grunberg joined LivaNova to raise awareness of seizures, drug-resistant epilepsy (DRE) and the available treatment options.